title: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
abstract: BACKGROUND
  The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) is the first primary-prevention study in a cohort with average total cholesterol (TC) and LDL cholesterol (LDL-C) and below-average HDL cholesterol (HDL-C). Treatment with lovastatin (20 to 40 mg/d) resulted in a 25% reduction in LDL-C and a 6% increase in HDL-C, as well as a 37% reduction in risk for first acute major coronary event (AMCE), defined as fatal or nonfatal myocardial infarction, unstable angina, or sudden cardiac death. This article describes the relation between baseline and on-treatment lipid and apolipoprotein (apo) parameters and subsequent risk for AMCEs.
  
  
  RESULTS
  With all available data from the entire 6605-patient cohort, a prespecified Cox backward stepwise regression model identified outcome predictors, and logistic regression models examined the relation between lipid variables and AMCE risk. Baseline LDL-C, HDL-C, and apoB were significant predictors of AMCE; only on-treatment apoB and the ratio of apoB to apoAI were predictive of subsequent risk; on-treatment LDL-C was not. When event rates were examined across tertiles of baseline lipids, a consistent benefit of treatment with lovastatin was observed.
  
  
  CONCLUSIONS
  Persons with average TC and LDL-C levels and below-average HDL-C may obtain significant clinical benefit from primary-prevention lipid modification. On-treatment apoB, especially when combined with apoAI to form the apoB/AI ratio, may be a more accurate predictor than LDL-C of risk for first AMCE.
authors.affiliation: Weill Medical College of Cornell University, New York, NY 10021, USA. amg_editorial@mail.med.cornell.edu
authors.forename: A M
authors.initials: AM
authors.lastname: Gotto
authors.forename: E
authors.initials: E
authors.lastname: Whitney
authors.forename: E A
authors.initials: EA
authors.lastname: Stein
authors.forename: D R
authors.initials: DR
authors.lastname: Shapiro
authors.forename: M
authors.initials: M
authors.lastname: Clearfield
authors.forename: S
authors.initials: S
authors.lastname: Weis
authors.forename: J Y
authors.initials: JY
authors.lastname: Jou
authors.forename: A
authors.initials: A
authors.lastname: Langendörfer
authors.forename: P A
authors.initials: PA
authors.lastname: Beere
authors.forename: D J
authors.initials: DJ
authors.lastname: Watson
authors.forename: J R
authors.initials: JR
authors.lastname: Downs
authors.forename: J S
authors.initials: JS
authors.lastname: de Cani
mesh_terms: D000208:Acute Disease; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001053:Apolipoproteins / Q000097:blood; D015331:Cohort Studies; D003324:Coronary Artery Disease / Q000097:blood* / Q000517:prevention & control; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008148:Lovastatin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008889:Military Personnel; D012044:Regression Analysis; D012307:Risk Factors; D013781:Texas
chemical_list: D000924:Anticholesteremic Agents; D001053:Apolipoproteins; D008055:Lipids; D008148:Lovastatin